Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Leap Therapeutics Inc (LPTX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Leap Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
3.1100 -0.1600    -4.89%
17:17:51 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 62,578
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 3.0500 - 3.3100
Type:  Equity
Market:  United States
Leap Therapeutics 3.1100 -0.1600 -4.89%

Leap Therapeutics Company Profile

 
Read the Leap Therapeutics Inc company profile to learn more about the business and the management team. View Leap Therapeutics Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

54

Equity Type

ORD

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Contact Information

Address 47 Thorndike Street Suite B1-1
Cambridge, 02141
United States
Phone 617 714 0360
Fax -

Top Executives

Name Age Since Title
Douglas E. Onsi 52 2011 CFO, General Counsel, Treasurer & Secretary, President, CEO & Director
Christopher K. Mirabelli 67 2011 Chairman
James H. Cavanaugh 84 2016 Independent Director
Thomas John Dietz 57 2016 Lead Independent Director
Joseph Loscalzo 70 2016 Independent Director
William W. Li 58 2017 Independent Director
Carl F. Nathan - - Member of Scientific Advisory Board
David Tuveson - - Member of Scientific Advisory Board
Nissim Mashiach 60 2017 Independent Director
Andrew B Nixon - 2021 Member of Scientific Advisory Board
Richard B. Gaynor 73 2021 Member of Scientific Advisory Board
Eileen M. O’Reilly - 2022 Member of Scientific Advisory Board
Richard L. Schilsky 73 2022 Independent Director
Patricia Martin 63 2023 Independent Director
Scott Joseph Antonia - 2023 Member of Scientific Advisory Board
Christian M. Richard 54 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

LPTX Price Commentary

Write your thoughts about Leap Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
LC Loo
LC Loo Mar 25, 2021 12:57
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Drug DKN-01 March 19 2021 Presentation
LC Loo
LC Loo Mar 25, 2021 12:57
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Drug DKN-01 March 19 2021
LC Loo
LC Loo Mar 25, 2021 12:56
Saved. See Saved Items.
This comment has already been saved in your Saved Items
DKN-01 March 19 2021
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email